Cargando…
Genotyping single nucleotide polymorphisms for allele-selective therapy in Huntington disease
BACKGROUND: The huntingtin gene (HTT) pathogenic cytosine-adenine-guanine (CAG) repeat expansion responsible for Huntington disease (HD) is phased with single nucleotide polymorphisms (SNPs), providing targets for allele-selective treatments. OBJECTIVE: This prospective observational study defined t...
Autores principales: | Claassen, Daniel O., Corey-Bloom, Jody, Dorsey, E. Ray, Edmondson, Mary, Kostyk, Sandra K., LeDoux, Mark S., Reilmann, Ralf, Rosas, H. Diana, Walker, Francis, Wheelock, Vicki, Svrzikapa, Nenad, Longo, Kenneth A., Goyal, Jaya, Hung, Serena, Panzara, Michael A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249892/ https://www.ncbi.nlm.nih.gov/pubmed/32548276 http://dx.doi.org/10.1212/NXG.0000000000000430 |
Ejemplares similares
-
Pharmacological treatment of chorea in Huntington’s disease–good clinical practice versus evidence-based guideline
por: Reilmann, Ralf
Publicado: (2013) -
Salivary levels of total huntingtin are elevated in Huntington’s disease patients
por: Corey-Bloom, Jody, et al.
Publicado: (2018) -
Assessing the state of care for Huntington disease in the United States: Results from a survey of practices treating Huntington disease patients
por: Seeberger, Lauren, et al.
Publicado: (2022) -
Plasma neurofilament light in Huntington’s disease: A marker for disease onset, but not symptom progression
por: Parkin, Georgia M., et al.
Publicado: (2021) -
Evaluation of Biochemical and Epigenetic Measures of Peripheral Brain-Derived Neurotrophic Factor (BDNF) as a Biomarker in Huntington’s Disease Patients
por: Gutierrez, Ashley, et al.
Publicado: (2020)